Your Feed

Filter by
See content from
Back to the latest
Avatar
Lisa521
Multiple Myeloma Discussion • June 30, 2025
Experiencing a Tough ASCT Recovery?
AI-generated title
I had my ASCT on May 23, 2025, about 6 weeks ago now, and I am still feeling awful. I am very weak and fatigued and feel as though I have been run over by a train with body aches all over my body. My appetite is still poor and I have recently begun vomiting after eating, not every meal but much more frequently than when I first had the transplant. I try to walk and move around but get very winded and have to stop and rest after going a very short distance. My doctor said that it can take 100 days to start feeling better. My blood results are great — white blood cell count, hemoglobin, platelets are all normal. Is what I am going through normal for other people who have had a transplant? I think I expected to start feeling better much and getting on with it much faster and am just wondering what other people’s experience has been. Thank you so much for your feedback.
Thumbnail for Venetoclax for AML: Shifting Care from Hospital to Clinic | Aaron Goldberg, MD, PhD | #EHA2025
Playlist: EHA 2025

Venetoclax for AML: Shifting Care from Hospital to Clinic | Aaron Goldberg, MD, PhD | #EHA2025

Video details & playlist
Thumbnail for Less Time in the Hospital: Real-World Benefits of Venetoclax for AML Patients | Aaron Goldberg, MD | #EHA2025
Playlist: EHA 2025

Less Time in the Hospital: Real-World Benefits of Venetoclax for AML Patients | Aaron Goldberg, MD | #EHA2025

Video details & playlist
Thumbnail for Promising New Combo Treatment Shows High Remission Rates in AML Patients with NPM1 and KMT2A Mutations | Harry Erba, MD | #EHA2025
Playlist: EHA 2025

Promising New Combo Treatment Shows High Remission Rates in AML Patients with NPM1 and KMT2A Mutations | Harry Erba, MD | #EHA2025

Video details & playlist
Thumbnail for Hope for Relapsed AML: Ziftomenib Shows Promise in NPM1-Mutated Leukemia | Eunice Wang, MD | #EHA2025
Playlist: EHA 2025

Hope for Relapsed AML: Ziftomenib Shows Promise in NPM1-Mutated Leukemia | Eunice Wang, MD | #EHA2025

Video details & playlist
Thumbnail for    Skip navigation Search    Create   Avatar image Implementation of Hospital-Level Care at Home for Acute Leukemia | Nikesh Shah, MD | #EHA 2025
Playlist: EHA 2025

Skip navigation Search Create Avatar image Implementation of Hospital-Level Care at Home for Acute Leukemia | Nikesh Shah, MD | #EHA 2025

Video details & playlist
Thumbnail for New Advances in Treating Acute Lymphoblastic Leukemia | Mark Litzow, MD | #EHA 2025
Playlist: EHA 2025

New Advances in Treating Acute Lymphoblastic Leukemia | Mark Litzow, MD | #EHA 2025

Video details & playlist
Thumbnail for Unmet Medical Needs of Patients Who are Lenalidomide Refractory | Claudio Cerchione, MD | #EHA2025
Playlist: EHA 2025

Unmet Medical Needs of Patients Who are Lenalidomide Refractory | Claudio Cerchione, MD | #EHA2025

Video details & playlist
Thumbnail for Improved Survival in Young B-ALL Patients with Blinatumomab | Mark Litzow, MD | #EHA 2025
Playlist: EHA 2025

Improved Survival in Young B-ALL Patients with Blinatumomab | Mark Litzow, MD | #EHA 2025

Video details & playlist
Thumbnail for Does Race Have an Impact on CLL Care? What the Latest Data? | Adam Kittai, MD #EHA2025
Playlist: EHA 2025

Does Race Have an Impact on CLL Care? What the Latest Data? | Adam Kittai, MD #EHA2025

Video details & playlist
Thumbnail for Advancing ET & Myelofibrosis Care: mutCALR Antibody Therapy | John Mascarenhas, MD | #EHA 2025
Playlist: EHA 2025

Advancing ET & Myelofibrosis Care: mutCALR Antibody Therapy | John Mascarenhas, MD | #EHA 2025

Video details & playlist